Physician profile
Sylvia E Walsh
NPI 1598740854
$1,498.96
in general payments reported to CMS, 2019-2025
21 companies · $274 in 2025
The $274 reported for 2025 was more than what 82% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2020: $115 · 2021: $412 · 2022: $174 · 2023: $185 · 2024: $181 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $640.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $640.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $256.69 | 2021-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $205.82 | 2021-2025 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $157.43 | 2021-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Glaxosmithkline, LLC. | $145.76 | 2019-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $142.33 | 2020-2025 | Mounjaro, Jardiance, Emgality |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.07 | 2020-2024 | Xifaxan |
| Exact Sciences Corporation | $78.51 | 2024-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $74.47 | 2019-2021 | |
| Dynavax Technologies Corporation | $49.45 | 2022-2023 | Heplisav-B |
| Janssen Pharmaceuticals, INC | $49.08 | 2021-2025 | Spravato |
| Dexcom, INC. | $36.64 | 2024-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $35.60 | 2023-2024 | |
| Genentech USA, INC. | $30.23 | 2020-2021 | |
| Abbvie INC. | $22.22 | 2025 | |
| Biogen, INC. | $21.13 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $21.11 | 2025 | Voquezna |
| Supernus Pharmaceuticals, INC. | $14.34 | 2022 | |
| Sanofi Pasteur INC. | $14.21 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.11 | 2022 | |
| Amgen INC. | $11.92 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.84 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sylvia Walsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.